title: Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours. A quantitative autoradiography study.
abstract: The density of omega 3 (peripheral type benzodiazepine) binding sites, a marker of reactive and tumoural cells, has been measured in different types of human brain tumours; omega 3 sites were quantified autoradiographically in sections from biopsy or autopsy specimens labelled with the specific radioligand 3H-PK 11195. Compared to normal brain parenchyma, up to 12-fold increase in omega 3 site densities were found in apparently viable areas of high grade astrocytoma and glioblastoma specimens, whereas more limited increases (2 to 3-fold) in this marker were observed in areas of necrosis. Low grade gliomas (astrocytomas) and meningiomas exhibited only moderate increases (2 to 3-fold) in this autoradiographic marker. Metastases of lung or kidney origin were characterized by greatly elevated (up to 20-fold) omega 3 site densities as compared to normal brain parenchyma. In every case, there was a good spatial correspondence between the histopathological limits of the tumour and the anatomical location of the increase in omega 3 site densities. These results suggest that omega 3 site densities in human brain tumours reflect their proliferative activity and point to a possible future usefulness of positron or gamma-ray emitting omega 3 site ligands for the clinical investigation and detection of human brain proliferative diseases.
authors.affiliation: Department of Neurosurgery, Hôpital de la Salpêtrière, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Cornu
authors.forename: J
authors.initials: J
authors.lastname: Benavides
authors.forename: B
authors.initials: B
authors.lastname: Scatton
authors.forename: J J
authors.initials: JJ
authors.lastname: Hauw
authors.forename: J
authors.initials: J
authors.lastname: Philippon
mesh_terms: D001254:Astrocytoma / Q000473:pathology; D001345:Autoradiography; D014408:Biomarkers, Tumor / Q000145:classification / Q000378:metabolism*; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology* / Q000556:secondary; D002528:Cerebellar Neoplasms / Q000473:pathology; D005910:Glioma / Q000473:pathology*; D006801:Humans; D007546:Isoquinolines / Q000493:pharmacokinetics; D008223:Lymphoma / Q000473:pathology; D008527:Medulloblastoma / Q000473:pathology; D008577:Meningeal Neoplasms / Q000473:pathology*; D008579:Meningioma / Q000473:pathology*; D011963:Receptors, GABA-A / Q000145:classification / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D007546:Isoquinolines; D011963:Receptors, GABA-A; C037850:PK 11195